Publications by authors named "Takao Tamura"
Background: The TRUSTY study evaluated the efficacy of second-line trifluridine/tipiracil (FTD/TPI) plus bevacizumab in metastatic colorectal cancer (mCRC).
Objective: This exploratory biomarker analysis of TRUSTY investigated the relationship between baseline plasma concentrations of angiogenesis-related factors and cell-free DNA (cfDNA), and the efficacy of FTD/TPI plus bevacizumab in patients with mCRC.
Patients And Methods: The disease control rate (DCR) and progression-free survival (PFS) were compared between baseline plasma samples of patients with high and low plasma concentrations (based on the median value) of angiogenesis-related factors.
Background: Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However, progression of non-measurable lesions and new lesions are frequently observed in patients with advanced gastric cancer (AGC).
Methods: This retrospective study involved AGC patients at 24 Japanese institutions who had measurable lesions and received nivolumab after ≥ 2 lines of chemotherapy.
Background: Primary tumor location is considered a predictor of overall survival (OS) in RAS wild-type (WT) metastatic colorectal cancer (mCRC) treated with bevacizumab (BEV) or an anti-epidermal growth factor antibody (cetuximab or panitumumab [CET/PAN]) as first-line molecularly targeted therapy. BEV is recommended for right-sided mCRC and CET/PAN for left-sided mCRC based on post-hoc analyses of clinical trial data, but real-world evidence is lacking.
Methods: We retrospectively collected data of patients who started BEV or CET/PAN plus 5-fluorouracil-based doublet chemotherapy between January 2013 and December 2016 as first-line treatment for RAS WT mCRC at any of 24 Japanese institutions.
Immune checkpoint inhibitors (ICIs) have markedly changed the treatment landscape for melanoma; however, their efficacy and applications are currently limited and medical requirements remain unmet. The present case study reports on a 85-year-old female patient who visited our outpatient clinic with a 1-month history of a buccal mucosa mass and was diagnosed with locally advanced mucosal melanoma of the head and neck. The patient's tumor progressed right after the administration of nivolumab, compromising oral intake.
View Article and Find Full Text PDFArticle Synopsis
- The ATTRACTION-2 study found that nivolumab monotherapy was more effective than placebo for patients with advanced gastric or gastroesophageal junction cancer, though some experienced early tumor progression.
- A post hoc analysis identified two key single factors (age and peritoneal metastasis) and two double-factor combinations (serum sodium level with white blood cell count and neutrophil-lymphocyte ratio) that could predict early disease progression and survival outcomes.
- Patients under 60 with peritoneal metastasis and low serum sodium levels may benefit less from nivolumab, while those 60 or older without peritoneal metastasis and with normal serum sodium levels may benefit more, indicating the importance of these combined factors in
Background: To compare irinotecan-alone, paclitaxel-alone, and each combination chemotherapy with S-1 in patients with advanced gastric cancer (AGC) that is refractory to S-1 or S-1 plus cisplatin (SP).
Methods: Patients with AGC after first-line chemotherapy with S-1 or SP, or patients during adjuvant chemotherapy or within 26 weeks after adjuvant chemotherapy completion with S-1 with confirmed disease progression were eligible. Patients were randomly divided into four groups based on treatment: irinotecan-alone (irinotecan; 150 mg/m, day 1, q14 days), paclitaxel-alone (paclitaxel; 80 mg/m, days 1, 8, 15, q28 days), S-1 plus irinotecan (irinotecan; 80 mg/m, days 1, 15, S-1; 80 mg/m, days 1-21, q35 days), and S-1 plus paclitaxel (paclitaxel; 50 mg/m, day1, 8, S-1; 80 mg/m, days 1-14, q21 days).
Background: Primary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced recently, the clinical impact of PTL in these treatments is not well understood.
Materials And Methods: We retrospectively evaluated patients with mCRC who were registered in a multicenter observational study (the REGOTAS study).
The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The present study evaluated the association between exposure to REG and TFTD and overall survival (OS) in patients with mCRC using data from the REGOTAS study.
View Article and Find Full Text PDFBackground: ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progression (TBP) with nivolumab have not been clarified.
Methods: The 3-year follow-up data were collected.
Background And Objective: Gastric cancer has been associated with notable geographic heterogeneity in previous multi-regional studies. In particular, patients from Japan have better outcomes compared with patients from other regions. Here, we assess patient-focused outcomes for the subgroup of Japanese patients in the global RAINBOW study.
View Article and Find Full Text PDFThe phase III West Japan Oncology Group (WJOG) 4407G study showed noninferiority of folinic acid, bolus/continuous fluorouracil, and irinotecan plus bevacizumab to modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin 6 plus bevacizumab in progression-free survival (PFS) as first-line chemotherapy for patients with metastatic colorectal cancer. The aim of this study was to evaluate the predictive and prognostic value of morphologic response in patients with colorectal liver metastases (CLM) as a post hoc analysis of the WJOG4407G study.Morphologic response was assessed by comparing contrast-enhanced computed tomography (CT) images at baseline and week 8.
View Article and Find Full Text PDFIntroduction: We report a case of conversion surgery for pancreatic ductal adenocarcinoma (PDAC) with synchronous distant metastases showing pathological complete response (pCR) after FOLFIRINOX therapy.
Presentation Of Case: A 46-year-old woman with obstructive jaundice was referred to our hospital. A CT scan revealed a hypo-vascular mass in the head of the pancreas with multiple para-aortic lymph nodes and a Virchow's node swollen.
Background/aim: This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC).
Patients And Methods: AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included.
Article Synopsis
- - The study evaluated the effectiveness of two drug combinations, panitumumab plus irinotecan and cetuximab plus irinotecan, in patients with metastatic colorectal cancer that didn't respond to prior treatments.
- - Results showed that patients receiving panitumumab had a median progression-free survival of 5.42 months, which was better than the 4.27 months for those on cetuximab, suggesting panitumumab could be superior.
- - However, the panitumumab group had a higher rate of severe hypomagnesaemia (17% compared to 7%), indicating a potential safety concern while still suggesting that panitumumab is likely effective for these patients.
Background: We previously reported the HERBIS-4A phase II trial comparing S-1 plus cisplatin (SP) with capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (GC). We performed a pooled analysis of HERBIS-4A and HERBIS-2, the phase II trial comparing SP with XP in HER2-negative recurrent GC patients with a recurrence-free interval after S-1 adjuvant therapy of ≥ 6 months.
Patients And Methods: Patients were randomly assigned to receive either SP [S-1 (40-60 mg twice daily for 21 days) plus cisplatin (60 mg/m on day 8), every 5 weeks] or XP [capecitabine (1000 mg/m twice daily for 14 days) plus cisplatin (80 mg/m on day 1), every 3 weeks].
Article Synopsis
- Nivolumab, an immunotherapy drug, showed significant improvements in overall survival (OS) for patients with gastric/gastroesophageal junction (G/GEJ) cancer who had received at least two previous chemotherapy regimens in the ATTRACTION-2 study.
- Results from a 2-year follow-up indicated that patients taking nivolumab had a median OS of 5.26 months compared to 4.14 months in the placebo group, with a notable survival advantage regardless of tumor PD-L1 expression.
- Notably, patients in the nivolumab group who achieved a complete or partial response had a median OS of 26.6 months, highlighting the long-term benefits of the treatment without new safety concerns
Article Synopsis
- A study evaluated the effectiveness of regorafenib and trifluridine/tipiracil (FTD/TPI) as treatments for metastatic colorectal cancer, recognizing that not all patients benefit equally.
- The research analyzed data from 489 patients using a multivariate approach to develop a prognostic score based on key clinical factors that could predict overall survival outcomes.
- This scoring system, which categorizes patients by low, moderate, and high survival benefit, could help identify those who would gain the most from these treatment options.
We retrospectively analyzed adverse effects(AEs), overall survival(OS), and progression-free survival(PFS)in 15 consecutive patients treated with FOLFIRINOX as the first-line treatment for recurrent or unresectable pancreatic ductal adenocarcinoma( PDAC)between February 2014 and December 2017 in our hospital. Eleven patients were treated for unresectable PDAC with distant metastases(UR-M), and 4 were treated for locally advanced unresectable PDAC(UR-LA). The median age was 56(range: 40-75)years.
View Article and Find Full Text PDFArticle Synopsis
- - A phase 3 clinical trial was conducted in Japan to compare the effectiveness of a treatment regimen including docetaxel, cisplatin, and S-1 versus a regimen of cisplatin and S-1 alone in patients with advanced gastric cancer who had not received prior chemotherapy.
- - A total of 741 patients were enrolled, with the primary goal being to measure overall survival rates between the two treatment groups.
- - The findings showed that the median overall survival was 14.2 months for the group receiving docetaxel plus cisplatin and S-1, compared to 15.3 months for the group receiving only cisplatin and S-1, indicating no significant survival advantage for the addition
Article Synopsis
- There is limited data on the effectiveness of immune checkpoint inhibitors like nivolumab in patients with advanced HER2-positive gastric/gastroesophageal junction (G/GEJ) cancer.
- In the ATTRACTION-2 phase 3 trial, researchers evaluated nivolumab's efficacy and safety in patients known to have previously received trastuzumab as a surrogate for HER2 status.
- Results showed that nivolumab significantly improved overall survival and progression-free survival compared to placebo in patients who were either trastuzumab-positive (Tmab+) or trastuzumab-negative (Tmab-), demonstrating its potential as a viable treatment option in this setting.
Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU) is believed to be a clinical option for improving clinical responses. Evaluating the potential factors contributing to plasma 5-FU concentration is important to develop TDM of 5-FU. Our aim was to evaluate the association of the circadian and treatment cycle effects on plasma 5-FU concentration with the clinical response.
View Article and Find Full Text PDFArticle Synopsis
- Nivolumab, an anti-PD-1 therapy, shows improved overall survival in Japanese patients with unresectable advanced G/GEJ cancer compared to placebo in the ATTRACTION-2 trial.
- The analysis involved 226 Japanese patients, revealing a median overall survival of 5.4 months for nivolumab versus 3.6 months for placebo, with a lower risk of death in the nivolumab group.
- Serious adverse events were comparably low in both treatment groups, and ongoing studies aim to further investigate the effects of nivolumab in patients previously treated with ramucirumab.
Article Synopsis
- A study compared the effectiveness of liquid-based endometrial cytology (LBEC) using SurePath™ and suction endometrial tissue biopsy (SETB) for detecting endometrial cancer, with findings published by the Japan Association of Obstetricians and Gynecologists.
- The research involved assessing over 2,000 specimens from five clinics, finding that LBEC had a sensitivity of 92.2% and a negative predictive value of 99.1%, slightly better than SETB's sensitivity of 85.2%.
- The results suggest that LBEC performs just as well as SETB for detecting endometrial malignancies, making it a suitable first-step tool for cancer detection and surveillance in women at risk.
Article Synopsis
- A study compared the effectiveness of two chemotherapy regimens, FOLFOX and FOLFIRI, combined with the drug bevacizumab for treating metastatic colorectal cancer (mCRC), finding similar results overall.
- Researchers analyzed tumor samples to identify gene copy number alterations that might help determine which treatment would be more beneficial for patients.
- Results indicated that specific gene alterations on chromosome 8q24.1-q24.2 could potentially serve as markers to guide the choice between FOLFOX and FOLFIRI for mCRC patients receiving bevacizumab.
Lessons Learned: The 5-fluorouracil, docetaxel, and nedaplatin (UDON) regimen was well tolerated and showed promising antitumor activity in terms of both objective response rate and survival for patients with advanced or recurrent esophageal squamous cell carcinoma in the first-line setting.UDON may be an optimal treatment option for patients with advanced esophageal cancer who are unfit for docetaxel, cisplatin, and 5-fluorouracil regimens.The high response rate as well as the rapid and marked tumor shrinkage associated with UDON suggest that further evaluation of this regimen in the neoadjuvant setting is warranted.
View Article and Find Full Text PDF